H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on CMPS stock, giving a Buy rating on June 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Patrick Trucchio has given his Buy rating due to a combination of factors including the positive outcomes from the Phase 3 COMP005 trial, which marked a regulatory milestone for COMP360 in treatment-resistant depression (TRD). The trial demonstrated significant improvement in depression symptoms, as measured by the MADRS scale, following a single dose of COMP360. This success is further bolstered by the ongoing COMP006 trial, which aims to explore the durability and re-dosing strategy of COMP360, with results expected in the second half of 2026.
Trucchio’s confidence in COMPASS Pathways is reinforced by the company’s strong clinical execution, safety profile, and regulatory strategy. The COMP005 trial’s use of a true placebo and rigorous trial design has set a new regulatory benchmark, despite the market’s muted reaction. Additionally, COMPASS Pathways is well-capitalized to continue its operations and invest in medical affairs and commercial planning, which supports the Buy rating and the $45 price target.
In another report released on June 30, Stifel Nicolaus also maintained a Buy rating on the stock with a $11.00 price target.